Table 3.
Effects of GLP-1RAs and SGLT2 Inhibitors on Hospitalization for Heart Failure in Meta-analyses
| First Author (Ref. #) | N | HR (95% CI) | P Value | P for Interaction |
|---|---|---|---|---|
| Kristensen et al (47) | 56,004 | |||
| GLP-1RA vs placebo | 0.91 (0.83-0.99) | 0.028 | ||
| Zelniker et al (46) | 34,322 | |||
| SGLT2i vs placebo | 0.69 (0.61-0.79) | <0.001 | ||
| History of HF | 0.68 (0.55-0.83) | 0.0002 | 0.76 | |
| No history of HF | 0.71 (0.60-0.83) | <0.0001 | ||
| Salah et al (26) | 59,747 | |||
| SGLT2i vs placebo (all patients) | 0.69 (0.64-0.74) | <0.000001 | ||
| SGLT2i vs placebo (patients with DM and HF) | 0.71 (0.61-0.83) | <0.0001 | ||
| SGLT2i vs placebo (patients with HF ± DM) | 0.69 (0.62-0.76) | <0.00001 |
DM = diabetes mellitus; HF = heart failure; other abbreviations as in Table 2.